Living with cutaneous T-cell lymphoma (CTCL) can be a challenge, but it’s a challenge that Therakos, Inc. is committed to helping you meet.
If you’ve been diagnosed with CTCL—or if someone you know has—this Web site is for you. Here you’ll find useful information on CTCL, and you’ll learn about a therapy designed to reduce the skin symptoms associated with the disorder: THERAKOS™ Photopheresis.
You are encouraged to report negative side effects of prescription drugs to the US Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Specially designed for medical professionals to use in their practice.
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen is not appropriate for patients who have had a reaction to psoralen compounds, patients who have had a light sensitive disease, or patients with an absence of one or both lenses of the eye.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate blood volume changes or patients with blood clotting disorders. See Important Safety Information for additional details.